obtained regulatory approval to assess the drug in Phase III trials for mild to moderate Covid-19. According to the company, Favipiravir demonstrated promising clinical evidence, with positive results in mild to moderate Covid-19 cases.
Clinical improvement was observed in age groups of 20 to >90 years.The drug is said to provide rapid decrease in viral load within four days, along with quicker symptomatic and radiological improvement.
Favipiravir demonstrated up to 88% of clinical improvement in patients with mild to moderate Covid-19. Glenmark said that mild to moderate Covid-19 patients with co-morbid conditions such as diabetes and heart disease can also use the drug.